indazoles has been researched along with Androgen-Independent Prostatic Cancer in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Chi, KN; Danila, DC; Efstathiou, E; Espina, BM; Fizazi, K; Francis, P; George, DJ; Lara, PN; Lopez-Gitlitz, A; Mason, GE; Olmos, D; Saad, F; Sandhu, S; Scher, HI; Smith, MR; Ståhl, O; Urtishak, KA; Yu, EY; Zhao, X | 1 |
| Bjartell, A; Sjöström, M | 1 |
| Anand, M; Armstrong, AJ; Barak, I; George, DJ; Halabi, S; Harrison, MR; Healy, P; Klein, M; Martinez, E; Nixon, AB; Szmulewitz, R; Wilder, R; Winters, C | 1 |
| Bradic, B; Chi, KN; De Meulder, M; Espina, BM; Francis, P; Graff, JN; Hayreh, V; Hazra, A; Lattouf, JB; Mamidi, RNVS; Posadas, EM; Rezazadeh Kalebasty, A; Saad, F; Shore, ND; Yu, A; Zhu, E | 1 |
| Du, X; Hu, D; Jiang, L; Luo, S; Tang, W; Tang, Y; Zhao, G; Zhao, X | 1 |
| Booth, CM; Chi, KN; Golubovic, J; Gregg, R; Harris, P; Joshua, AM; Murray, N; Sridhar, SS; Wang, L | 1 |
| Affolter, T; Christensen, J; Eisele, K; Eswaraka, J; Feng, Z; Giddabasappa, A; Han, G; Lalwani, K; Li, G | 1 |
4 trial(s) available for indazoles and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
Topics: Adolescent; Adult; Androgen Antagonists; Androgens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; DNA Repair; Humans; Indazoles; Male; Piperidines; Prostatic Neoplasms, Castration-Resistant; Thrombocytopenia | 2022 |
Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Sulfonamides; Survival Rate; Treatment Outcome | 2019 |
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE).
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Indazoles; Male; Middle Aged; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prednisone; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Thiohydantoins | 2021 |
A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Humans; Indazoles; Kallikreins; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Sulfonamides; Tosyl Compounds; Treatment Outcome | 2015 |
3 other study(ies) available for indazoles and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Indazoles; Male; Piperidines; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2023 |
NPRL2 reduces the niraparib sensitivity of castration-resistant prostate cancer via interacting with UBE2M and enhancing neddylation.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Atlases as Topic; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Databases, Genetic; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NEDD8 Protein; Piperidines; Prostatic Neoplasms, Castration-Resistant; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Signal Transduction; Survival Analysis; Tumor Suppressor Proteins; Ubiquitin-Conjugating Enzymes; Xenograft Model Antitumor Assays | 2021 |
Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bone Density; Bone Neoplasms; Cell Line, Tumor; Crizotinib; Humans; Imidazoles; Indazoles; Male; Mice, Inbred NOD; Mice, SCID; Prostatic Neoplasms, Castration-Resistant; Pyrazoles; Pyridines; Xenograft Model Antitumor Assays | 2014 |